Stifel Financial’s Catalyst Pharmaceutical CPRX Stock Holding History

Stifel Financial’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$661K	Sell	21,023 -196,128	-90%	-$5.79M	﹤0.01%	2800
2026 Q1	$5.38M	Buy	217,151 +40,126	+23%	+$956K	﹤0.01%	1308
2025 Q4	$4.13M	Buy	177,025 +76,993	+77%	+$1.72M	﹤0.01%	1435
2025 Q3	$1.97M	Sell	100,032 -1,082	-1%	-$22.3K	﹤0.01%	1928
2025 Q2	$2.19M	Buy	101,114 +83,515	+475%	+$1.97M	﹤0.01%	1781
2025 Q1	$427K	Buy	+17,599	New	+$396K	﹤0.01%	2791
2015 Q2	–	Sell	-35,000	Closed	-$152K	–	2364
2015 Q1	$152K	Buy	+35,000	New	+$126K	﹤0.01%	2153

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Stifel Financial's CPRX Position: Q2 2026 in Review

Stifel Financial reduced its Catalyst Pharmaceutical (CPRX) stake by 90% in Q2 2026, selling an estimated $5.79M and leaving 21,023 shares worth $661K. The position accounts for ﹤0.01% of the portfolio, ranked #2800.

Stifel Financial first reported a position in CPRX in Q1 2015 and has held it in 7 quarters since. The position peaked at $5.38M in Q1 2026. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

Stifel Financial held 21,023 shares of Catalyst Pharmaceutical worth $661K as of Q2 2026.
Stifel Financial sold 196,128 Catalyst Pharmaceutical shares in Q2 2026, an estimated $5.79M.
Catalyst Pharmaceutical made up ﹤0.01% of Stifel Financial's portfolio in Q2 2026, its #2800 holding.
Stifel Financial first reported a position in Catalyst Pharmaceutical in Q1 2015 and has held it in 7 quarters since.
Stifel Financial's Catalyst Pharmaceutical position peaked at $5.38M in Q1 2026.
396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Stifel Financial's 13F filing for Q2 2026, filed 12 Aug 2026.